Press release
Von Willebrand Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix
DelveInsight's "Von Willebrand Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Von Willebrand Disease, historical and forecasted epidemiology as well as the Von Willebrand Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Von Willebrand Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Von Willebrand Disease Market Forecast [https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Von Willebrand Disease Market Report:
*
The Von Willebrand Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In April 2024, Octapharma USA, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug exclusivity for wilate Registered , a lyophilized powder of von Willebrand Factor/Coagulation Factor VIII Complex (Human) for intravenous injection. This approval is specifically for routine prophylaxis aimed at reducing the frequency of bleeding episodes in adults and children aged 6 and older who have von Willebrand disease (VWD).
*
In 2023, the total diagnosed prevalent cases of von Willebrand disease in the US were around 13,000, with projections indicating an increase throughout the study period (2020-2034).
*
In 2023, females made up approximately 55% of the diagnosed prevalent cases of von Willebrand disease in the US, representing over 7,000 cases.
*
In 2023, the 5-13 and 14-18 age groups accounted for approximately 32% and 22% of all diagnosed prevalent cases of von Willebrand disease in the US. The 0-4, 19-44, and over 45 age groups represented around 6%, 23%, and 17% of cases, respectively.
*
In 2023, Type 2 and Type 3 von Willebrand disease constituted approximately 11% and 6% of all diagnosed cases in the US, respectively. In contrast, Type 1 von Willebrand disease accounted for about 83% of cases alone.
*
Key Von Willebrand Disease Companies: Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix Corp., and others
*
Key Von Willebrand Disease Therapies: Wilate, plasma-derived FVIII/VWF concentrate, Biostate Registered , Voncento, Oprelvekin, Interleukin 11, IL-11, Alphanate SD/HT, rVWF, ARC1779, and others
*
The Von Willebrand Disease epidemiology based on gender analyzed that females are affected more as compared to males, in case of Von Willebrand disease (VWD)
*
The Von Willebrand Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Von Willebrand Disease pipeline products will significantly revolutionize the Von Willebrand Disease market dynamics.
Von Willebrand Disease Overview
Von Willebrand disease (VWD) is a genetic blood disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a protein involved in blood clotting. VWF helps platelets stick together and adhere to blood vessel walls, promoting clot formation and preventing excessive bleeding.
Get a Free sample for the Von Willebrand Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market [https://www.delveinsight.com/report-store/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Von Willebrand Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Von Willebrand Disease Epidemiology Segmentation:
The Von Willebrand Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Von Willebrand Disease
*
Prevalent Cases of Von Willebrand Disease by severity
*
Gender-specific Prevalence of Von Willebrand Disease
*
Diagnosed Cases of Episodic and Chronic Von Willebrand Disease
Download the report to understand which factors are driving Von Willebrand Disease epidemiology trends @ Von Willebrand Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Von Willebrand Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Von Willebrand Disease market or expected to get launched during the study period. The analysis covers Von Willebrand Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Von Willebrand Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Von Willebrand Disease Therapies and Key Companies
*
Wilate: Octapharma
*
plasma-derived FVIII/VWF concentrate: Grifols Therapeutics LLC
*
Biostate Registered : CSL Behring
*
Voncento: CSL Behring
*
Oprelvekin, Interleukin 11, IL-11: Margaret Ragni
*
Alphanate SD/HT: Grifols Biologicals, LLC
*
rVWF: Baxalta now part of Shire
*
ARC1779: Archemix Corp.
Discover more about therapies set to grab major Von Willebrand Disease market share @ Von Willebrand Disease Treatment Landscape [https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Von Willebrand Disease Market Drivers
*
Rise in Von Willebrand Disease (VWD) market is attributed to several factors such as increasing prevalence, evolving research, more diagnostic tests, and novel systemic therapies.
Von Willebrand Disease Market Barriers
*
Due to lack of competitors in Von Willebrand Disease, there is a substantial market opportunity for key players to develop Von Willebrand Diseasetargeting therapies.
Scope of the Von Willebrand Disease Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Von Willebrand Disease Companies: Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix Corp., and others
*
Key Von Willebrand Disease Therapies: Wilate, plasma-derived FVIII/VWF concentrate, Biostate Registered , Voncento, Oprelvekin, Interleukin 11, IL-11, Alphanate SD/HT, rVWF, ARC1779, and others
*
Von Willebrand Disease Therapeutic Assessment: Von Willebrand Disease current marketed and Von Willebrand Disease emerging therapies
*
Von Willebrand Disease Market Dynamics: Von Willebrand Disease market drivers and Von Willebrand Disease market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Von Willebrand Disease Unmet Needs, KOL's views, Analyst's views, Von Willebrand Disease Market Access and Reimbursement
To know more about Von Willebrand Disease companies working in the treatment market, visit @ Von Willebrand Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/von-willebrand-disease-vwd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Von Willebrand Disease Market Report Introduction
2. Executive Summary for Von Willebrand Disease
3. SWOT analysis of Von Willebrand Disease
4. Von Willebrand Disease Patient Share (%) Overview at a Glance
5. Von Willebrand Disease Market Overview at a Glance
6. Von Willebrand Disease Disease Background and Overview
7. Von Willebrand Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Von Willebrand Disease
9. Von Willebrand Disease Current Treatment and Medical Practices
10. Von Willebrand Disease Unmet Needs
11. Von Willebrand Disease Emerging Therapies
12. Von Willebrand Disease Market Outlook
13. Country-Wise Von Willebrand Disease Market Analysis (2020-2034)
14. Von Willebrand Disease Market Access and Reimbursement of Therapies
15. Von Willebrand Disease Market Drivers
16. Von Willebrand Disease Market Barriers
17. Von Willebrand Disease Appendix
18. Von Willebrand Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=von-willebrand-disease-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-octapharma-grifols-therapeutics-llc-csl-behring-margaret-ragni-shire-archemix]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Von Willebrand Disease Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Octapharma, Grifols Therapeutics LLC, CSL Behring, Margaret Ragni, Shire, Archemix here
News-ID: 3710394 • Views: …
More Releases from ABNewswire
Funk Fest Returns to New Orleans This October with Three Days of Funk, Food, and …
Funk Fest returns to New Orleans October 17-19, 2025, with three days of nonstop groove at Spanish Plaza. Featuring three stages of authentic NOLA funk including Galactic, Dumpstaphunk, Master P with the Soul Rebels, George Porter Jr., and Big Chief Juan Pardo's Tribal Gold the festival blends legendary music with the city's cultural heartbeat. From Black Masking Indians to immaculate vibes and tasty food, Funk Fest is New Orleans at…
ALL Trial Lawyers' Mohammad Abuershaid Named Super Lawyers Rising Star for Sixth …
Image: https://dashboard.kingnewswire.com/uploads/press-release/2025/08/29/175648649868b1db6239a56175648649868b1db6239a58.png
Los Angeles, CA - ALL Trial Lawyers announced today that Mohammad Abuershaid, a prominent CPS defense attorney and juvenile dependency lawyer serving Los Angeles, San Bernardino, Riverside, and Orange counties, has been named a Super Lawyers Rising Star for the sixth consecutive year, covering 2020 through 2025, with recognition anticipated again in 2026.
This distinction, awarded to only 2.5 percent of attorneys in Southern California, highlights Abuershaid's reputation as one…
New Book Gatekeeping Your Marriage Covenant Empowers Couples to Build Strong, Go …
Authors Taquetta Baker and Praise Asemota, through Kingdom Shifters Ministries, announce the release of their new book Gatekeeping Your Marriage Covenant (ISBN: 9798990810648), a comprehensive Christian manual for singles, engaged couples, and married partners seeking to strengthen and protect their marriages through God's divine design.
Marriage, as created by God, reflects His love, unity, and faithfulness. In Gatekeeping Your Marriage Covenant, Baker and Asemota draw from Ephesians 5 to illustrate how…
Author's Tranquility Press Presents Trends Due to Climate Change: A Witness to t …
A 50-Year Journal of One Backyard's Silent Battle Against Time, Memory, and a Warming Planet
Somewhere in a quiet corner of Allentown, Pennsylvania, the past five decades have been quietly recorded in the shape of a maple leaf, the silence of an absent bird, the stubborn warmth of a January breeze. Now, for the first time, the world can read the story the planet has been whispering all along.
Author's Tranquility Press…
More Releases for Willebrand
Von Willebrand Disease Treatment Market Statistical Forecast, Trade Analysis 202 …
DataM Intelligence has published a new research report on "Von Willebrand Disease Treatment Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.
Get a Free Sample Research…
Von Willebrand Disease Treatment Market Size 2024 to 2031.
Market Overview and Report Coverage
Von Willebrand Disease is a rare inherited bleeding disorder that affects the blood's ability to clot properly. The Von Willebrand Disease Treatment Market encompasses medications, blood transfusions, and other therapies aimed at managing the symptoms and improving the quality of life for patients with this condition.
The future outlook for the Von Willebrand Disease Treatment Market is promising, with a projected growth at a CAGR…
Acquired von Willebrand Disease (AvWD) Treatment Market Size, Analysis And Forec …
Acquired von Willebrand syndrome is a highly heterogeneous bleeding disorder, that usually displays mild to moderate hemorrhagic symptoms that may at times be severe too. Many a time the severity increases post-surgery. AvWS is considered a rare disorder, however, the actual prevalence is not as rare. In case the laboratory findings diagnose vWD in a patient with no family history, AvWS-associated conditions are usually explored. The acquired von Willebrand disease…
Norway Von Willebrand Disease Treatment Market Trends, Current Demand, and Busin …
According to a Transparency Market Research (TMR) research report, the global von willebrand disease treatment market is expected to reach ~US$ 900 Mn by the end of 2030. This suggests that the market is likely to expand at a CAGR of ~6% during the forecast period, 2020 to 2030.
The business intelligence study on the market is prepared by employing industry-validated primary and secondary methods. The study uses these to collect…
Growing Healthcare Expenditure Lead To Extensive Sales In Von Willebrand Disease …
The Fact.MR report offers insight into the Competitive Dynamic in Von Willebrand Disease Treatment Market which has shaped the major strategies of each player. It also covers recent moves such as partnerships and collaborations, mergers and acquisitions, diversification and research investments, of each prominent player.
The key factors that shape the entry barrier and intensity of competition in the Von Willebrand Disease Treatment market are presented in the analysis. Further, the…
Von Willebrand disease treatment therapies and Von Willebrand Disease treatment …
The research report presents a comprehensive assessment of the Von Willebrand Disease Treatment Market and contains thoughtful insights, facts, historical data and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to market segments such as geographies, application and industry
To remain ‘ahead’ of your competitors, request for a sample - https://www.factmr.com/connectus/sample?flag=S&rep_id=1496
Von Willebrand Disease…
